Dasatinib-Induced Pleural and Pericardial Effusions

Chronic myeloid leukemia (CML) is a myeloproliferative disease associated with the Philadelphia chromosome and BCR-ABL1 fusion gene. Tyrosine kinase inhibitors (TKI) are now the standard therapy for this condition. Among the approved TKIs for CML is dasatinib. We present a case of a 58-year-old Egyp...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2021-10, Vol.13 (10)
Main Authors: Hailan, Yousef M, Elyas, Ahmed, Abdulla, Mohammad A, Yassin, Mohamed A
Format: Article
Language:English
Subjects:
Cardiology
Case reports
Drug dosages
FDA approval
Hematology
Internal Medicine
Leukemia
Pathogenesis
Patients
Pleural effusion
Severe acute respiratory syndrome coronavirus 2
Steroids
Tuberculosis
X-rays
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic myeloid leukemia (CML) is a myeloproliferative disease associated with the Philadelphia chromosome and BCR-ABL1 fusion gene. Tyrosine kinase inhibitors (TKI) are now the standard therapy for this condition. Among the approved TKIs for CML is dasatinib. We present a case of a 58-year-old Egyptian male who developed bilateral pleural (grade II) as well as pericardial effusions (grade II) secondary to dasatinib 100 mg once-daily dosing. He was managed by interrupting dasatinib and introducing diuretics and steroids. The objective is to raise awareness about this unfavorable effect as it may affect the patient's quality of life and increase rates of treatment withdrawal.
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.19024